Apr 30, 2019
GenePOC, a Subsidiary of Debiopharm Group, Reaches an Agreement With Meridian Bioscience for the Acquisition of Their Molecular Diagnostics Business
Mar 21, 2019
GenePOC Obtains FDA Clearance for its GenePOC(TM) Strep A Test in the US
Feb 14, 2019
Debiopharm International SA Initiates FUZE, a Clinical Trial Phase II Study Evaluating Debio 1347 in Advanced Solid Tumors Harboring an FGFR fusion
Jan 07, 2019
Debiopharm Group Regains the Commercial Rights to Trelstar® (Triptorelin pamoate) and Looks for New Partners in North America
Oct 23, 2018
GenePOC® Launches its GenePOC® CDiff Test in Canada
Oct 11, 2018
Debiopharm International SA and the Paul Scherrer Institute Announce a Licensing Agreement for the Development of a Novel Targeted Radiotherapeutic Product in Oncology
May 08, 2018
FDA Grants Fast Track Designation to Debiopharm International's Debio 1347 for the Treatment of Patients With Unresectable or Metastatic Tumors With a Specific FGFR Gene Alteration
Feb 15, 2018
Debiopharm Continues the Fight Against Antibiotic Resistance With Investment in ABAC Therapeutics Inc.
Nov 22, 2017
Debiopharm International SA Launches Clinical Trials Website: patients.debiopharm.com
Nov 14, 2017
EMA Grants Orphan Drug Designation to Debiopharm International SA's FGFR Inhibitor Debio 1347 in the Treatment of Biliary Tract Cancer
Nov 06, 2017
Debiopharm International SA Announces Dosing of First Patient in a Combination Trial of Debio 1143 and Avelumab in Patients with Solid Tumors including Non-Small Cell Lung Cancer (NSCLC)
Jul 25, 2017
Debiopharm International SA Awarded $2.6 Million Grant from CARB-X to Support Development of Debio 1453 to Fight Drug Resistant Gonorrhea
Jun 28, 2017
GenePOC Announces an Exclusive Distribution Agreement with Cardinal Health Covering the US Market
Jun 20, 2017
Almac Discovery and Debiopharm International SA Announce a Licensing Agreement for the Development of a Novel Wee-1 Inhibitor
Jun 15, 2017
Debiopharm International SA Announces Completion of Enrollment in Phase I/II Clinical Trial with Debio 1143 in SCCHN
Jun 01, 2017
Debiopharm International SA Announces Results from Phase I Dose-Escalation Study of Debio 1347/CH5183284